Basics CRISPR Therapeutics AG CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. IPO Date: October 19, 2016 Sector: Healthcare Industry: Biotech Market Cap: $4.55B Activated in VL: True Average Daily Range Avg Daily Range: $1.62 | 2.80% Avg Daily Range (30 D): $1.45 | 2.79% Avg Daily Range (90 D): $1.17 | 2.80% Institutional Daily Volume Avg Daily Volume: 1.14M Avg Daily Volume (30 D): 3.29M Avg Daily Volume (90 D): 2.4M Trade Size Avg Trade Size (Sh.): 64 Avg Trade Size (Sh.) (30 D): 63 Avg Trade Size (Sh.) (90 D): 63 Institutional Trades Total Inst.Trades: 5,519 Avg Inst. Trade: $2.81M Avg Inst. Trade (30 D): $4.96M Avg Inst. Trade (90 D): $3.66M Avg Inst. Trade Volume: .04M Avg Inst. Trades (Per Day): 3 Market Closing Trades Avg Closing Trade: $5.16M Avg Closing Trade (30 D): $20.06M Avg Closing Trade (90 D): $10.14M Avg Closing Volume: 80.03K     News Jul 21, 2025 @ 4:07 AM 3 Monster Stocks in the Making to Buy Right Now Source: Multiple Motley Fool Contributors Jul 9, 2025 @ 12:30 PM Breaking Through: Systemic Genetic Medicines for H... Source: Prnewswire Jun 26, 2025 @ 11:00 AM CRISPR Therapeutics Reports Positive Additional Ph... Source: Crispr Therapeutics Jun 24, 2025 @ 8:17 AM The Best Stocks to Invest $1,000 in Right Now Source: James Brumley Jun 17, 2025 @ 2:07 PM Editas Medicine Is Great. Here's Why You Shouldn't... Source: Dan Victor Financials   TTM Q4 2024 FY 2024 Basic EPS $-1.58 $-.42 $-4.34 Diluted EPS $-1.58 $-.42 $-4.34 Revenue $ .87M $ 35.69M $ 37.31M Gross Profit $ $ $ Net Income / Loss $ -136M $ -37.31M $ -366.25M Operating Income / Loss $ -148.42M $ -64.59M $ -466.57M Cost of Revenue $ $ $ Net Cash Flow $ -63.11M $ 72.67M $ -91.27M PE Ratio